Merck & Co Inc (MRK)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Also measured against its sector ETF (XBI).
Our last 30 days of resolved calls came true 18% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+61% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityRich valuation (P/E 148)-2
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is **none** — these headlines are sector commentary and peer earnings (Gilead, Regeneron), not Merck-specific news, so there's no clear company catalyst driving MRK. Continuation probability is low-to-moderate (~30–40%), since without a Merck-specific driver any move is more likely to reflect broad biotech/macro drift than persist. Informational only — not financial advice.
- Business Development Supports Merck & Co.’s (MRK) Next Growth ChapterYahoo · 2026-11-05
- Moderna Soared 8% on Cancer Data. Friday’s Report Shows Whether It Can Afford the PipelineYahoo · 2026-11-05
- Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for LillyYahoo · 2026-11-05
- Messenger Ribonucleic Acid (mRNA) Manufacturing Service Market Report 2026 | Capitalize on 16.2% CAGR in IVT and LNP with Thermo Fisher, Merck, Lonza and GenScript ProBioYahoo · 2026-11-05
- What Changed In Bristol Myers Squibb's Story?Yahoo · 2026-11-05
Any AI summary is an interpretation of public news, not advice or a price target.